檢索結果 - Xiao-Yan Ma

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer

    Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer 由 Li Liao, Yin-Ling Zhang, Ling Deng, Chao Chen, Xiao-Yan Ma, Lisa Andriani, Shao‐Ying Yang, Shu‐Yuan Hu, Fang-Lin Zhang, Zhimin Shao, Da‐Qiang Li

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer

    Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer 由 Fanglin Zhang, Shao‐Ying Yang, Li Liao, Tai‐Mei Zhang, Yinling Zhang, Shu‐Yuan Hu, Ling Deng, Min-Ying Huang, Lisa Andriani, Xiao-Yan Ma, Zhimin Shao, Da‐Qiang Li

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1

    SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1 由 Ling Deng, Li Liao, Yin‐Ling Zhang, Shao‐Ying Yang, Shu‐Yuan Hu, Lisa Andriani, Yun-Xiao Ling, Xiao-Yan Ma, Fang-Lin Zhang, Zhi‐Ming Shao, Da‐Qiang Li

    出版 2024
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

    Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models 由 Zebin Wang, Kaiming Sun, Yonghong Xiao, Bin Feng, Keith Mikule, XiaoYan Ma, Ningping Feng, Christopher P. Vellano, Lorenzo Federico, Joseph R. Marszalek, Gordon B. Mills, Jeffrey H. Hanke, Sridhar Ramaswamy, Jing Wang

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    In vivo multidimensional CRISPR screens identify <i>Lgals2</i> as an immunotherapy target in triple-negative breast cancer

    In vivo multidimensional CRISPR screens identify <i>Lgals2</i> as an immunotherapy target in triple-negative breast cancer 由 Peng Ji, Yue Gong, Ming‐Liang Jin, Huailiang Wu, Linwei Guo, Yu‐Chen Pei, Wen-Jun Chai, Yi‐Zhou Jiang, Yin Liu, Xiao-Yan Ma, Gen-Hong Di, Xin Hu, Zhi‐Ming Shao

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer

    CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer 由 Song‐Yang Wu, Si-Wei Zhang, Ding Ma, Yi Xiao, Yin Liu, Li Chen, Xiao-Qing Song, Xiao-Yan Ma, Ying Xu, Wen-Jun Chai, Xi Jin, Zhi-Ming Shao, Yi‐Zhou Jiang

    出版 2023
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

    Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial 由 Song‐Yang Wu, Ying Xu, Li Chen, Lei Fan, Xiao-Yan Ma, Shen Zhao, Xiao-Qing Song, Xin Hu, Wentao Yang, Wen-Jun Chai, Xiaomao Guo, Xi-Zi Chen, Yanhui Xu, Xiaoyu Zhu, Jianjun Zou, Zhonghua Wang, Yi‐Zhou Jiang, Zhi-Ming Shao

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

    Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial 由 Li Chen, Yi‐Zhou Jiang, Song‐Yang Wu, Jiong Wu, Gen‐Hong Di, Guang‐Yu Liu, Ke‐Da Yu, Lei Fan, Junjie Li, Yifeng Hou, Zhen Hu, Canming Chen, Xiaoyan Huang, A‐Yong Cao, Xin Hu, Shen Zhao, Xiao-Yan Ma, Ying Xu, Xiangjie Sun, Wen-Jun Chai, Xiaomao Guo, Xizi Chen, Yanhui Xu, Xiaoyu Zhu, Jianjun Zou, Wentao Yang, Zhonghua Wang, Zhi‐Ming Shao

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

    Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy 由 Christopher P. Vellano, Michael G. White, Miles C. Andrews, Manoj Chelvanambi, Russell G. Witt, Joseph R. Daniele, Mark Titus, Jennifer L. McQuade, Fabio Conforti, Elizabeth M. Burton, Matthew Lastrapes, Gabriel O Ologun, Alexandria P. Cogdill, Golnaz Morad, Peter A. Prieto, Alexander J. Lazar, Yanshuo Chu, Guangchun Han, M.A. Wadud Khan, Beth A. Helmink, Michael A. Davies, Rodabe N. Amaria, Jeffrey J. Kovacs, Scott E. Woodman, Sapna P. Patel, Patrick Hwu, Michael Peoples, Jeffrey E. Lee, Zachary A. Cooper, Haifeng Zhu, Guang R. Gao, Hiya Banerjee, Mike Lau, Jeffrey E. Gershenwald, Anthony Lucci, Emily Z. Keung, Merrick I. Ross, Laura Pala, Eleonora Pagan, Rossana Lazcano Segura, Qian Liu, Mikayla Borthwick, Eric Lau, Melinda S. Yates, Shannon N. Westin, Khalida Wani, Michael T. Tetzlaff, Lauren E. Haydu, Mikhila Mahendra, Xiao-Yan Ma, Christopher J. Logothetis, Zachary Kulstad, Sarah Johnson, Courtney W. Hudgens, Ningping Feng, Lorenzo Federico, Georgina V. Long, P. Andrew Futreal, Swathi Arur, Hussein A. Tawbi, Amy E. Moran, Linghua Wang, Timothy P. Heffernan, Joseph R. Marszalek, Jennifer A. Wargo

    出版 2022
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: